Rizact

Rizact - pills swallowed for the urgent care of the headache phase within the attacks of migraines. This Cipla product is a great painkillerthanks to an action of Rizatriptan, which is characterized by an analgesic effect.

Product dosage: 10mg
Package (num)	Per pill	Price	Buy
8	$8.00	$64.00 (0%)	🛒 Add to cart
12	$7.42	$96.00 $89.00 (7%)	🛒 Add to cart
24	$6.92	$192.00 $166.00 (14%)	🛒 Add to cart
36	$6.50	$288.00 $234.00 (19%)	🛒 Add to cart
60	$6.10	$480.00 $366.00 (24%)	🛒 Add to cart
88	$5.80 Best per pill	$704.00 $510.00 (28%)	🛒 Add to cart

Product dosage: 5mg
Package (num)	Per pill	Price	Buy
8	$6.38	$51.00 (0%)	🛒 Add to cart
12	$6.00	$76.50 $72.00 (6%)	🛒 Add to cart
24	$5.58	$153.00 $134.00 (12%)	🛒 Add to cart
36	$5.19	$229.50 $187.00 (19%)	🛒 Add to cart
60	$4.80	$382.50 $288.00 (25%)	🛒 Add to cart
88	$4.60 Best per pill	$561.00 $405.00 (28%)	🛒 Add to cart

Rizact is a prescription medication specifically formulated for the acute treatment of migraine attacks with or without aura in adults. It is not indicated for the prophylactic management of migraine. Containing the active ingredient rizatriptan benzoate, a selective serotonin (5-HT1B/1D) receptor agonist, Rizact works by constricting dilated cranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides from the trigeminal nerve, thereby targeting the underlying pathophysiology of a migraine attack. This article provides a comprehensive, expert-level overview of its pharmacology, appropriate use, and essential safety information for healthcare professionals and informed patients.

Features

• Active Ingredient: Rizatriptan Benzoate (available in 5 mg and 10 mg orally disintegrating tablets and standard tablets).
• Pharmacologic Class: Selective Serotonin Receptor Agonist (Triptan).
• Mechanism of Action: Binds with high affinity to 5-HT1B and 5-HT1D receptors.
• Rapid Administration: Orally disintegrating tablet (ODT) formulation dissolves on the tongue without the need for water, ideal for nausea.
• Rapid Absorption: Demonstrated bioavailability and quick onset of action.
• Dosage Forms: Standard oral tablets and orally disintegrating tablets for patient preference and compliance.

Benefits

• Provides effective and rapid relief from the debilitating pain of a migraine attack, often within 2 hours for a significant proportion of patients.
• Effectively addresses the full constellation of migraine symptoms, including nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound).
• The orally disintegrating tablet format offers a significant advantage for patients who experience severe nausea and vomiting during an attack, making swallowing a standard pill difficult.
• Helps restore normal function and allows patients to resume daily activities more quickly by aborting the migraine process.
• Offers a proven and well-established treatment option within the triptan class, with a substantial body of clinical evidence supporting its efficacy and safety profile.
• Provides a sense of control for migraine sufferers, allowing for prompt treatment at the first signs of an attack.

Common use

Rizact is exclusively indicated for the acute treatment of migraine attacks with or without aura in adults. It is most effective when taken at the very onset of migraine pain. It is not intended for the prevention of migraines or for the treatment of other types of headache (e.g., cluster headaches). A single dose should be taken to treat an ongoing attack. If a patient does not respond to the first dose, a second dose for the same attack is not recommended, as efficacy has not been established. However, if the headache recurs after initial relief, a second dose may be taken, provided at least 2 hours have elapsed since the first dose. The safety of treating more than four headaches in a 30-day period has not been established.

Dosage and direction

The recommended dose is either 5 mg or 10 mg. The choice of dose should be individualized, weighing the potential for greater efficacy with the 10 mg dose against the increased risk of adverse events. For patients on prophylactic therapy with propranolol, a dose adjustment is necessary: the recommended dose of Rizact is 5 mg, with a maximum of 3 doses in any 24-hour period (maximum 15 mg). For all other patients, the maximum dose is 30 mg in any 24-hour period.

Directions for Use:

• Standard Tablet: Swallow the tablet whole with water.
• Orally Disintegrating Tablet (ODT): Remove the blister pack from the foil pouch with dry hands. Do not push the tablet through the foil. Peel open the blister pack and place the tablet on the tongue. The tablet will dissolve rapidly and can be swallowed with saliva. No water is needed for administration.

Precautions

Rizact should be used with caution in patients with risk factors for coronary artery disease (e.g., hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history, or postmenopausal women) unless a cardiovascular evaluation provides satisfactory evidence that the patient is free of underlying cardiovascular disease. As triptans can cause coronary vasoconstriction, they are not recommended for use in patients with documented ischemic or vasospastic coronary artery disease. It should be used with caution in patients with hepatic impairment, as clearance may be reduced. Patients with phenylketonuria (PKU) should be advised that the ODT formulation contains aspartame, a source of phenylalanine. Rizact should only be used where a clear diagnosis of migraine has been established.

Contraindications

Rizact is contraindicated in patients with:

• History of ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, documented silent ischemia).
• Coronary artery vasospasm, including Prinzmetal’s angina.
• Uncontrolled hypertension.
• History of stroke or transient ischemic attack (TIA).
• Peripheral vascular disease.
• Ischemic bowel disease.
• Hypersensitivity to rizatriptan or any component of the formulation.
• Concurrent administration or within 24 hours of use of another 5-HT1 agonist (e.g., another triptan) or ergotamine-containing or ergot-type medication (e.g., dihydroergotamine, methysergide).
• Concurrent administration or within 2 weeks of discontinuation of a monoamine oxidase (MAO) A inhibitor.

Possible side effect

The most common adverse reactions are generally mild and transient.

• Very Common (≥1/10): Dizziness, somnolence (sleepiness/drowsiness).
• Common (≥1/100 to <1/10): Fatigue, asthenia (weakness), nausea, dry mouth, chest pain/tightness/pressure (often non-cardiac in origin), palpitations, tachycardia, pain (e.g., in the neck, throat, or jaw).
• Uncommon (≥1/1,000 to <1/100): Hypertension, hypotension, bradycardia, syncope, abdominal pain, diarrhea, vomiting, muscle weakness, paresthesia (tingling), tremor, agitation, anxiety, insomnia, blurred vision.
• Rare: Serious cardiac events (myocardial infarction, arrhythmias), cerebral hemorrhage, subarachnoid hemorrhage, stroke, and serotonin syndrome (particularly when used concomitantly with other serotonergic drugs).

Drug interaction

Significant and potentially dangerous drug interactions exist.

• Monoamine Oxidase Inhibitors (MAOIs): Contraindicated. Concomitant use significantly increases rizatriptan plasma levels and the risk of serotonin syndrome.
• Propranolol: Increases the plasma concentration of rizatriptan by approximately 70%. Dose adjustment to 5 mg is mandatory, with a maximum daily dose of 15 mg.
• Other Triptans and Ergot Derivatives: Contraindicated due to additive vasoconstrictive effects, increasing the risk of prolonged vasospastic reactions.
• Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Concomitant use may potentially lead to serotonin syndrome, characterized by agitation, hallucinations, tachycardia, hyperthermia, and autonomic instability. Caution is advised.
• Other Serotonergic Drugs: (e.g., tricyclic antidepressants, mirtazapine, fentanyl, lithium, tramadol, St. John’s Wort) may also increase the risk of serotonin syndrome.

Missed dose

Rizact is not scheduled for regular daily use; it is taken on an as-needed basis at the onset of a migraine attack. Therefore, the concept of a “missed dose” does not apply. The medication should only be taken when a migraine headache is present.

Overdose

There is limited clinical experience with overdose. The symptoms would be an exaggeration of the known adverse effects, including dizziness, drowsiness, bradycardia, hypotension, syncope, and vomiting. In cases of significant overdose, vasospastic reactions or serotonin syndrome are serious theoretical risks. There is no specific antidote. Treatment consists of supportive measures, including continuous ECG monitoring for at least 24 hours, and management of symptoms. Hemodialysis is unlikely to be beneficial due to the drug’s large volume of distribution.

Storage

Store at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light and moisture. Keep the ODT tablets in their original blister package within the foil pouch until the moment of use to protect them from moisture. Keep all medications out of the reach of children and pets.

Disclaimer

This information is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various sources believed to be accurate but cannot be guaranteed. The manufacturer’s official prescribing information is the ultimate authority.

Reviews

• “As a neurologist with over 20 years of practice, rizatriptan remains a first-line cornerstone in my acute migraine treatment arsenal. Its rapid onset, especially the ODT formulation, provides reliable relief for a majority of my patients. The key is proper patient selection and education on early administration.” – Dr. Eleanor Vance, MD, Neurology
• “The disintegrating tablet is a game-changer. My migraines always come with horrible nausea, and trying to swallow a pill was a guaranteed way to make it worse. Being able to take this without water means I can actually get my medication down and start feeling better faster.” – Sarah K.
• “Clinical trial data consistently shows rizatriptan 10 mg provides headache pain freedom at 2 hours in a significant percentage of patients, alongside relief of associated symptoms. Its pharmacokinetic profile supports its use for rapid abortive therapy.” – Clinical Pharmacologist Review
• “I’ve tried several triptans, and Rizact works the fastest for me. I experience some tightness in my jaw and chest, which my doctor warned me about, but it’s a tolerable trade-off for the migraine pain vanishing within 90 minutes.” – Mark T.
• “It is imperative for prescribers to rigorously assess cardiovascular risk factors before initiating any triptan, including rizatriptan. While an excellent therapeutic option, its vasoactive properties demand respect and caution.” – Cardiology Advisory